ATE534736T1 - Identifizierungsverfahren und verbindungen für die behandlung degenerativer und entzündlicher erkrankungen - Google Patents
Identifizierungsverfahren und verbindungen für die behandlung degenerativer und entzündlicher erkrankungenInfo
- Publication number
- ATE534736T1 ATE534736T1 AT05774134T AT05774134T ATE534736T1 AT E534736 T1 ATE534736 T1 AT E534736T1 AT 05774134 T AT05774134 T AT 05774134T AT 05774134 T AT05774134 T AT 05774134T AT E534736 T1 ATE534736 T1 AT E534736T1
- Authority
- AT
- Austria
- Prior art keywords
- degenerative
- compounds
- treatment
- inflammatory diseases
- identification methods
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 230000003412 degenerative effect Effects 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 208000027866 inflammatory disease Diseases 0.000 title 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 abstract 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 abstract 2
- 230000015556 catabolic process Effects 0.000 abstract 2
- 238000006731 degradation reaction Methods 0.000 abstract 2
- 210000002744 extracellular matrix Anatomy 0.000 abstract 2
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- 230000003110 anti-inflammatory effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000007423 screening assay Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
- C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6489—Metalloendopeptidases (3.4.24)
- C12N9/6491—Matrix metalloproteases [MMP's], e.g. interstitial collagenase (3.4.24.7); Stromelysins (3.4.24.17; 3.2.1.22); Matrilysin (3.4.24.23)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/10—Applications; Uses in screening processes
- C12N2320/12—Applications; Uses in screening processes in functional genomics, i.e. for the determination of gene function
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
- G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
- G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
- G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
- G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
- G01N2333/96486—Metalloendopeptidases (3.4.24)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/10—Musculoskeletal or connective tissue disorders
- G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
- G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Urology & Nephrology (AREA)
- Analytical Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pathology (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Plant Pathology (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Cell Biology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US57930704P | 2004-06-14 | 2004-06-14 | |
| PCT/EP2005/052754 WO2005121778A2 (en) | 2004-06-14 | 2005-06-14 | Methods for identification, and compounds useful for the treatment of degenerative & inflammatory diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE534736T1 true ATE534736T1 (de) | 2011-12-15 |
Family
ID=35503767
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT05774134T ATE534736T1 (de) | 2004-06-14 | 2005-06-14 | Identifizierungsverfahren und verbindungen für die behandlung degenerativer und entzündlicher erkrankungen |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US7306923B2 (cg-RX-API-DMAC7.html) |
| EP (4) | EP2270160A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2008502355A (cg-RX-API-DMAC7.html) |
| AT (1) | ATE534736T1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2569511A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MXPA06014577A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2005121778A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7485468B2 (en) * | 2004-10-15 | 2009-02-03 | Galapagos Bv | Molecular targets and compounds, and methods to identify the same, useful in the treatment of joint degenerative and inflammatory diseases |
| JP2009520466A (ja) * | 2005-12-22 | 2009-05-28 | エニス，ジエーン | 凍結臍帯組織由来の生存可能な細胞 |
| JP2010538244A (ja) | 2007-06-20 | 2010-12-09 | ガラパゴス・ナムローゼ・フェンノートシャップ | 骨及び関節の変性疾患の治療に有用な分子標的及び化合物並びにその同定方法 |
| TW200918099A (en) | 2007-09-14 | 2009-05-01 | Nitto Denko Corp | Drug carriers |
| US8450397B2 (en) * | 2007-09-25 | 2013-05-28 | Dunlop Sports Co. Ltd. | Golf ball |
| DE102007059839A1 (de) | 2007-12-11 | 2009-06-25 | Harald Dipl.-Ing. Feuerherm | Schlauchförmiger Vorformling und Herstellung blasgeformter Teile und Verfahren sowie Vorrichtung zur Herstellung des Vorformlings |
| CN102171239B (zh) | 2008-09-24 | 2018-11-13 | 特尔哈肖梅尔医学研究基础设施和服务有限公司 | 用于防止细胞粘附的肽和组合物及其使用方法 |
| AU2015224504B2 (en) * | 2008-12-29 | 2018-02-22 | Tel Hashomer Medical Research, Infrastructure And Services Ltd | Peptides and compositions for prevention of cell adhesion and methods of using same |
| US11174299B2 (en) | 2008-12-29 | 2021-11-16 | Dispersebio Ltd. | Peptides and compositions for prevention of cell adhesion and methods of using same |
| SG172244A1 (en) | 2008-12-29 | 2011-07-28 | Tel Hashomer Medical Res Infrastructure & Services Ltd | Peptides and compositions for prevention of cell adhesion and methods of using same |
| EP3043179B1 (en) * | 2009-04-01 | 2020-05-06 | Galapagos N.V. | Methods and means for treatment of osteoarthritis |
| AU2013216983A1 (en) * | 2012-02-07 | 2014-09-18 | La Jolla Institute For Allergy And Immunology | Epitopes from allergen proteins and methods and uses for immune response modulation |
| US20160138027A1 (en) * | 2013-03-14 | 2016-05-19 | The Board Of Trustees Of The Leland Stanford Junior University | Treatment of diseases and conditions associated with dysregulation of mammalian target of rapamycin complex 1 (mtorc1) |
| EP3682034A1 (en) * | 2017-09-13 | 2020-07-22 | Alexera AB | Methods for identifying therapeutic agents which interact with stk24 |
| EP4090371A4 (en) * | 2020-01-14 | 2024-04-03 | The Trustees of Columbia University in the City of New York | Compositions and methods for targeted protein stabilization by redirecting endogenous deubiquitinases |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US5354844A (en) | 1989-03-16 | 1994-10-11 | Boehringer Ingelheim International Gmbh | Protein-polycation conjugates |
| US5693622A (en) | 1989-03-21 | 1997-12-02 | Vical Incorporated | Expression of exogenous polynucleotide sequences cardiac muscle of a mammal |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
| AU4769893A (en) | 1992-07-17 | 1994-02-14 | Ribozyme Pharmaceuticals, Inc. | Method and reagent for treatment of animal diseases |
| FR2714830B1 (fr) | 1994-01-10 | 1996-03-22 | Rhone Poulenc Rorer Sa | Composition contenant des acides nucléiques, préparation et utilisations. |
| FR2715847B1 (fr) | 1994-02-08 | 1996-04-12 | Rhone Poulenc Rorer Sa | Composition contenant des acides nucléiques, préparation et utilisations. |
| FR2727679B1 (fr) | 1994-12-05 | 1997-01-03 | Rhone Poulenc Rorer Sa | Nouveaux agents de transfection et leurs applications pharmaceutiques |
| FR2730637B1 (fr) | 1995-02-17 | 1997-03-28 | Rhone Poulenc Rorer Sa | Composition pharmaceutique contenant des acides nucleiques, et ses utilisations |
| EP1051499A2 (en) | 1998-01-29 | 2000-11-15 | The Board of Regents of the University of Oklahoma | Tyrosylprotein sulfotransferase polypeptides and polynucleotides |
| WO2000014250A1 (en) | 1998-09-09 | 2000-03-16 | The Board Of Regents Of The University Of Oklahoma | Tyrosylprotein sulfotransferase polypeptides and polynucleotides |
| CA2319700C (en) * | 1998-02-13 | 2011-09-20 | The Wistar Institute | Methods of identifying genes involved in enhanced wound healing in mice |
| US6413776B1 (en) | 1998-06-12 | 2002-07-02 | Galapagos Geonomics N.V. | High throughput screening of gene function using adenoviral libraries for functional genomics applications |
| US20020151681A1 (en) * | 1999-03-12 | 2002-10-17 | Rosen Craig A. | Nucleic acids, proteins and antibodies |
| US20050112118A1 (en) * | 1999-12-02 | 2005-05-26 | Myriad Genetics, Incorporated | Compositions and methods for treating inflammatory disorders |
| US7332337B2 (en) | 2000-05-16 | 2008-02-19 | Galapagos Nv | Viral vectors having tissue tropism for T-lymphocytes, B- and mast cells |
| US7235233B2 (en) | 2000-09-26 | 2007-06-26 | Crucell Holland B.V. | Serotype 5 adenoviral vectors with chimeric fibers for gene delivery in skeletal muscle cells or myoblasts |
| US20020132823A1 (en) | 2001-01-17 | 2002-09-19 | Jiahuai Han | Assay method |
| AU2002253104A1 (en) | 2001-03-07 | 2002-09-19 | Galapagos Genomics B.V. | Adenoviral library assay for e2f regulatory genes and methods and compositions for screening compounds |
| US6537780B2 (en) | 2001-03-28 | 2003-03-25 | Applera Corporation | Isolated nucleic acid molecules encoding transferase enzymes |
| US6426221B1 (en) * | 2001-08-01 | 2002-07-30 | Isis Pharmaceuticals, Inc. | Antisense modulation of RIP2 expression |
| US20030198627A1 (en) | 2001-09-01 | 2003-10-23 | Gert-Jan Arts | siRNA knockout assay method and constructs |
| JP2005522999A (ja) * | 2002-01-31 | 2005-08-04 | ミレニアム・ファーマシューティカルズ・インコーポレイテッド | 癌を処置するための方法および組成物 |
| WO2004024097A2 (en) * | 2002-09-16 | 2004-03-25 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| AU2003286711A1 (en) | 2002-10-25 | 2004-05-13 | Vertex Pharmaceuticals Incorporated | Indazolinone compositions useful as kinase inhibitors |
| JP2006515747A (ja) * | 2002-11-01 | 2006-06-08 | ジェネンテック・インコーポレーテッド | 免疫関連疾患の治療のための組成物と方法 |
| CA2513148A1 (en) * | 2003-01-23 | 2004-08-05 | Eirx Therapeutics Limited | Kinases and gpcrs involved in apoptosis |
| EP1618209A2 (en) * | 2003-04-18 | 2006-01-25 | Novartis AG | High throughput functional genomic screening methods for osteoarthritis |
| AU2003224132A1 (en) | 2003-04-24 | 2004-11-19 | Galapagos Genomics N.V. | Effective sirna knock-down constructs |
| DE10328033A1 (de) | 2003-06-19 | 2005-01-05 | Bläß, Stefan, Dr. | Verfahren und ArthritisChip zur Diagnostik, Verlaufskontrolle sowie zur Charakterisierung der rheumatoiden Arthritis und der Osteoarthrose |
| AU2004262369A1 (en) * | 2003-07-29 | 2005-02-10 | Bristol-Myers Squibb Company | Biomarkers of cyclin-dependent kinase modulation |
| US7485468B2 (en) * | 2004-10-15 | 2009-02-03 | Galapagos Bv | Molecular targets and compounds, and methods to identify the same, useful in the treatment of joint degenerative and inflammatory diseases |
-
2005
- 2005-06-14 EP EP10174541A patent/EP2270160A1/en not_active Withdrawn
- 2005-06-14 EP EP05774134A patent/EP1773997B1/en not_active Expired - Lifetime
- 2005-06-14 MX MXPA06014577A patent/MXPA06014577A/es active IP Right Grant
- 2005-06-14 US US11/152,366 patent/US7306923B2/en not_active Expired - Fee Related
- 2005-06-14 CA CA002569511A patent/CA2569511A1/en not_active Abandoned
- 2005-06-14 AT AT05774134T patent/ATE534736T1/de active
- 2005-06-14 EP EP10174539A patent/EP2256197A1/en not_active Withdrawn
- 2005-06-14 EP EP10174544A patent/EP2256198A1/en not_active Withdrawn
- 2005-06-14 JP JP2007526437A patent/JP2008502355A/ja active Pending
- 2005-06-14 WO PCT/EP2005/052754 patent/WO2005121778A2/en not_active Ceased
-
2007
- 2007-09-12 US US11/854,037 patent/US7919259B2/en not_active Expired - Fee Related
-
2011
- 2011-02-01 US US13/019,142 patent/US20110118140A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP2256197A1 (en) | 2010-12-01 |
| CA2569511A1 (en) | 2005-12-22 |
| US7919259B2 (en) | 2011-04-05 |
| US20110118140A1 (en) | 2011-05-19 |
| US20060014184A1 (en) | 2006-01-19 |
| MXPA06014577A (es) | 2007-03-23 |
| WO2005121778B1 (en) | 2007-02-01 |
| EP2270160A1 (en) | 2011-01-05 |
| WO2005121778A3 (en) | 2006-11-23 |
| US7306923B2 (en) | 2007-12-11 |
| EP1773997B1 (en) | 2011-11-23 |
| EP1773997A2 (en) | 2007-04-18 |
| WO2005121778A2 (en) | 2005-12-22 |
| JP2008502355A (ja) | 2008-01-31 |
| US20090062137A1 (en) | 2009-03-05 |
| EP2256198A1 (en) | 2010-12-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE534736T1 (de) | Identifizierungsverfahren und verbindungen für die behandlung degenerativer und entzündlicher erkrankungen | |
| ECSP055719A (es) | Compuestos de tiazol para el tratamiento de trastornos neurodegenerativos | |
| MA28935B1 (fr) | Preparation et utilisation de derives de biphenyl-4-yl-carbonylamino-acide dans le traitement de l'obesite | |
| DOP2005000040A (es) | Compuestos de imidazol para el tratamiento de trastornos neurodegenerativos | |
| UY28450A1 (es) | Compuestos heteroarilo de 6 miembros para el tratamiento de trastornos neurodegenerativos. | |
| DE602004029580D1 (de) | Substituierte indolderivate für eine pharmazeutische zusammensetzung zur behandlung von atemwegserkrankungen | |
| EP1841426A4 (en) | ACTIVE TERTIARY CARBINAMINES WITH SUBSTITUTED HETEROCYCLES FOR THE TREATMENT OF ALZHEIMER DISEASE AS INHIBITORS OF BETA-SECRETASE | |
| BRPI0407662B8 (pt) | derivados do ácido 1-fenilalcanocarboxílico para o tratamento de doenças neurodegenerativas | |
| UY28279A1 (es) | Fenacilo 2 -hidroxi - 3 - diaminoalcanos | |
| PA8583601A1 (es) | Derivados de pirrolidona como inhibidores de maob | |
| UY28101A1 (es) | Ureas substituidas y carbamatos útiles para el tratamiento de la enfermedad de alzheimer | |
| UY28484A1 (es) | Compuestos para el tratamiento de trastornos neurodegenerativos | |
| BRPI0610644B8 (pt) | composto e composição farmacêutica que compreende tal composto e um veículo ou diluente farmaceuticamente aceitável. | |
| NO20076405L (no) | Anvendelse av 24-nor-UDCA | |
| ATE371724T1 (de) | Behandlung neurodegenerativer krankheiten | |
| BR0315462A (pt) | Composto, composição farmacêutica, uso de um composto, método para o tratamento de um sujeito que sofre de uma condição patológica ou de doença susceptìvel de alìvio por antagonismo de receptores de ltd4 e produto de combinação | |
| MX2009012525A (es) | Pirazol-pirrolidinas como inhibidores de gamma secretasa. | |
| DE60326069D1 (de) | 4-(heterocyclyl)-benzenesulfoximin verbindungen zur behandlung entzündlicher erkrankungenen | |
| EP1817312A4 (en) | MACROCYCLIC AMINIOPYRIDYL BETA SEKRETASE INHIBITORS FOR THE TREATMENT OF MORBUS ALZHEIMER | |
| TW200716152A (en) | Substituted 1,2-ethylendiamines, medicaments comprising said compound, their use and their method of manufacture | |
| ECSP088280A (es) | Compuestos de imidazol para el tratamiento de trastornos neurológicos | |
| UY28825A1 (es) | Compuestos de sulfonamidas para el tratamiento de trastornos neurodegenerativos | |
| UY28458A1 (es) | Compuestos de oxazol para el tratamiento de trastornos neurodegenerativos | |
| MX2009013482A (es) | Derivados de [1,10]-fenantrolina para el tratamiento de enfermedades neurodegenerativas o hematologicas. | |
| ATE399758T1 (de) | Derivate von 1-phenylalkancarbonsäuren zur behandlung von neurodegenerativen krankheiten |